Edition:
United Kingdom

Alliqua BioMedical Inc (ALQA.OQ)

ALQA.OQ on NASDAQ Stock Exchange Capital Market

2.13USD
13 Dec 2018
Change (% chg)

$-0.19 (-7.99%)
Prev Close
$2.32
Open
$2.27
Day's High
$2.35
Day's Low
$2.13
Volume
97,823
Avg. Vol
149,917
52-wk High
$5.23
52-wk Low
$1.58

Latest Key Developments (Source: Significant Developments)

Alliqua Biomedical To Spin Off & Merge Its Contract Manufacturing Business To Pharmaceuticals Llc
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Alliqua BioMedical Inc ::ALLIQUA BIOMEDICAL TO SPIN OFF AND MERGE ITS CONTRACT MANUFACTURING BUSINESS WITH TO PHARMACEUTICALS LLC TO CREATE AN INDEPENDENT, PUBLICLY TRADED COMPANY FOCUSED ON CANNABINOID-BASED PHARMACEUTICAL THERAPIES.ALLIQUA BIOMEDICAL INC - FORMER SHAREHOLDERS WILL RETAIN A MINORITY STAKE WITH FORMER MEMBERS OF TOP HOLDING A MAJORITY INTEREST IN TO PHARMA.ALLIQUA BIOMEDICAL INC - UPON CLOSING, AQUAMED WILL BE RENAMED TO PHARMA AND WILL BE HEADQUARTERED IN LANGHORNE, PENNSYLVANIA.ALLIQUA BIOMEDICAL INC - TO PHARMA INTENDS TO APPLY TO LIST ITS SHARES OF COMMON STOCK ON NASDAQ STOCK MARKET.ALLIQUA BIOMEDICAL INC - MERGER WILL BE STRUCTURED AS AN EQUITY EXCHANGE.ALLIQUA BIOMEDICAL INC - WILL DISTRIBUTE SHARES OF COMMON STOCK OF AQUAMED ON A PRO RATA BASIS TO RECORD HOLDERS OF ALLIQUA.ALLIQUA BIOMEDICAL INC - MERGER WILL BE STRUCTURED AS AN EQUITY EXCHANGE.ALLIQUA BIOMEDICAL - TOP'S SETH YAKATAN EXPECTED TO SERVE AS CEO AND ALLIQUA'S DAVID JOHNSON TO SERVE AS CHAIRMAN OF BOARD OF COMBINED CO.ALLIQUA BIOMEDICAL INC - TRANSACTION HAS BEEN APPROVED BY BOARDS OF BOTH ALLIQUA AND TOP.ALLIQUA BIOMEDICAL INC -UNIT AQUAMED TECHNOLOGIES, INC. TO MERGE WITH TOP TO CREATE A NEW LISTED CO.  Full Article

Alliqua Biomedical Terminates Credit Agreement & Guaranty Dated May 29, 2015
Monday, 7 May 2018 

May 7 (Reuters) - Alliqua BioMedical Inc ::ALLIQUA BIOMEDICAL SAYS ON MAY 7,IN RELATION TO COMPLETION OF ASSET SALE, CO TERMINATED CREDIT AGREEMENT & GUARANTY DATED MAY 29, 2015 - SEC FILING.ALLIQUA BIOMEDICAL INC - CO ALSO TERMINATED RELATED PLEDGE AND SECURITY AGREEMENT, DATED AS OF MAY 29, 2015.  Full Article

Alliqua Biomedical Says Has Right To Terminate Agreement With Celularity, Provided Co Pays $1.45 Mln Fee
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Alliqua Biomedical Inc ::ALLIQUA BIOMEDICAL SAYS HAS RIGHT TO TERMINATE ASSET PURCHASE AGREEMENT WITH CELULARITY, PROVIDED CO PAYS TERMINATION FEE OF $1.45 MILLION - SEC FILING.ALLIQUA BIOMEDICAL INC - CELULARITY MAY BE OBLIGATED TO PAY A $3 MILLION REVERSE TERMINATION FEE IF ASSET PURCHASE AGREEMENT IS TERMINATED BY CO.  Full Article

Alliqua Biomedical Announces Definitive Asset Purchase Agreement With Celularity Inc
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Alliqua Biomedical Inc ::ALLIQUA BIOMEDICAL, INC. ANNOUNCES DEFINITIVE ASSET PURCHASE AGREEMENT WITH CELULARITY, INC..ALLIQUA BIOMEDICAL INC - DEAL FOR $29.0 MILLION.ALLIQUA BIOMEDICAL - AS PER DEAL, CELULARITY WILL ACQUIRE ALL OF PROPERTY, ASSETS AND RIGHTS RELATING TO CO'S ADVANCED BIOLOGIC WOUND CARE BUSINESS.ALLIQUA BIOMEDICAL - AS PER DEAL, CELULARITY WILL ALSO ACQUIRE ALL OF PROPERTY, ASSETS AND RIGHTS RELATING TO CO'S ULTRAMIST THERAPY SYSTEM.ALLIQUA BIOMEDICAL INC - CO'S BOARD OF DIRECTORS UNANIMOUSLY APPROVED ENTERING INTO AGREEMENT.ALLIQUA BIOMEDICAL INC - NO DEBT OR SIGNIFICANT LIABILITIES ARE BEING ASSUMED BY CELULARITY IN TRANSACTION.  Full Article

Alliqua BioMedical engages Cowen to assist in evaluating potential strategic alternatives
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Alliqua BioMedical Inc :Alliqua BioMedical Inc engages Cowen to assist in evaluating potential strategic alternatives.Alliqua BioMedical Inc - engaged Cowen as its independent financial advisor to assist co in evaluating potential strategic alternatives​.  Full Article

Alliqua Biomedical says co and Celgene entered into side letter agreement
Wednesday, 15 Mar 2017 

Alliqua Biomedical Inc : On March 13, 2017, co and Celgene entered into a side letter agreement - sec filing . co, chairman Jerome Zeldis entered into side letter agreement; Zeldis to conditionally waive MFN adjustment in securities purchase deal . Celgene agreed to waive MFN adjustment in spa to extent MFN adjustment would cause Celgene to own in excess of 19.9% of co's common stock Further company coverage: [ALQA.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article